FDA Brief

Warning letters Drugs

FDA warning letter to

"Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases

High riskIssued Apr 5, 2022Posted Apr 19, 2022Center for Drug Evaluation and Research | CDER

FDA warns clinical investigator Daniel C. Tarquinio over enrolling ineligible subjects in investigational drug trials.

What happened

FDA inspected the clinical site from October 18 and November 5, 2021, under its program for inspecting clinical research and reviewed the investigator’s response to inspection findings. FDA found that four subjects were enrolled in an investigational drug protocol and then an open-label extension even though each was already enrolled and participating in another clinical study, contrary to the investigational plans’ exclusion criteria.

What FDA found

  1. Failed to ensure the clinical investigation was conducted according to the investigational plan.

    21 CFR 312.60
  2. Enrolled subjects who did not meet eligibility criteria because they were already participating in another clinical study.

    21 CFR 312.60

What FDA wants

Within 15 business days, notify FDA in writing of actions taken to prevent similar violations. FDA also tells the investigator to address the deficiencies and ensure ongoing or future studies comply with FDA regulations.

Who should pay attention

  • clinical research sites
  • sponsors and contract research organizations running trials
  • IRBs overseeing enrollment

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Nana Barseghian, M.D.

    FDA warns clinical investigator Nana Barseghian for enrolling high-body-mass-index subjects in drug trials despite protocol exclusion.

    High risk
  2. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  3. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  4. Smitha C. Reddy, M.D./ACRC Studies, LLC

    FDA warns Dr. Smitha Reddy over clinical trial protocol violations, including wrong drug given and broken blinding.

    High risk